0000000000793840

AUTHOR

C. De Carli

showing 2 related works from this author

Rapporto costo-efficacia della terapia peginterferone α-2a + ribavirina in confronto a interferone α-2b + ribavirina in pazienti affetti da epatite c…

2004

Introduction In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost-effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost.

business.industryHealth PolicyRibavirinvirus diseasesVirologydigestive system diseasesVirological responsechemistry.chemical_compoundchemistryChronic hepatitisInterferonmedicinePharmacology (medical)businessmedicine.drugPharmacoEconomics Italian Research Articles
researchProduct

PIN31: THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HE…

2003

medicine.medical_specialtyCost effectivenessbusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthGastroenterologychemistry.chemical_compoundchemistryChronic hepatitisInternal medicinemedicinebusinessInterferon alfamedicine.drugPeginterferon alfa-2aValue in Health
researchProduct